Recombinant Human Endostatin

Jiangsu SimPros Pharmaceuticals Ltd. is affiliated with Simcere Pharmaceutical Group Limited (HKEX: 2096), an innovation-driven pharmaceutical company committed to for-patients, for-life values across oncology, central nervous system, autoimmune and anti-infection therapeutic areas. Since its founding as Jiangsu Cuccess Pharmaceutical in 1995 and rebranding as Simcere in 1999, the group has developed and commercialized notable innovative drugs including Endostar (China's first Category I antitumor new drug, 2006), Bicun (Edaravone Injection) and Iremod (Iguratimod Tablets), listed on the NYSE in 2007, and forged strategic partnerships with BMS, Daiichi Sankyo and Amgen for biosimilar and antitumor drug co-development; Mylan is among its customers. The manufacturer, trading company and other-role business supplies finished dosage antibiotic and antiviral, antipyretic and analgesic, nervous system, anti-tumor, and cardiovascular/cerebrovascular preparations worldwide, drawing on an established brand, internationally approved standards, an experienced R&D team, strong production capacity and contract manufacturing capability.